Opna Bio Launches With $38 Million Series A Financing To Advance Novel Oncology Discovery Program And Diversified Pipeline Of Clinical And Preclinical Programs
Amount Raised
$38 Million
Round Type
Series A
LausanneBiotechnologyHealth CareTherapeuticsBiopharmaInvestors
Description
Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that it has raised $38 million in a Series A financing, led by Longitude Capital and Northpond Ventures, with additional participation from Menlo Ventures. The proceeds will be used to develop novel fragile-X mental retardation protein (FMRP) inhibitors in oncology as well as a diverse portfolio of clinical and preclinical oncology programs acquired from Plexxikon Inc.
Quick answer
Opna Bio raised $38 Million in a Series A round, dated November 21, 2022. Investors: Menlo Ventures, Northpond Ventures and Longitude Capital. Opna Bio is based in Lausanne, Vaud, Switzerland.
- How much did Opna Bio raise?
- Opna Bio raised $38 Million in a Series A round on November 21, 2022.
- Who invested in Opna Bio?
- Menlo Ventures, Northpond Ventures and Longitude Capital are named as investors in this round.
- What does Opna Bio do?
- Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics.
- Where is Opna Bio based and how big is it?
- Opna Bio is based in Lausanne, Vaud, Switzerland.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biopharma around the same time
Companies in the same sectors as Opna Bio that raised within 45 days of this round, from Fundz verified event records.
- HighTide Therapeutics raised $107M (Series C) on January 5, 2023.
- GenSight Biologics raised $13M (Convertible Note) on December 23, 2022.
- Madrigal Pharmaceuticals raised $300M (Funding Round) on December 21, 2022.
- Alpha-9 Theranostics raised $75M (Series B) on December 14, 2022.
- Parabilis Medicines raised $178M (Series D) on November 21, 2022.
- Parabilis Medicines raised $178M on November 17, 2022.
Who to call at Opna Bio, and when
A new round usually means Opna Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Opna Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Opna Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Opna Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Opna Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansOpna Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.